Organon (NYSE: OGN), the U.S.-based pharmaceutical company, has reported its fourth-quarter 2023 financial results, revealing a 3% year-on-year increase in global revenues, reaching USD 6.3 billion in constant currencies. The company’s performance showed marked improvement, with Q4 revenues climbing 8% year-on-year to USD 1.6 billion.
Breaking down Q4 performance by business unit, Women’s Health sales rose 8% to USD 465 million, while Biosimilars surged 48% to USD 199 million. Established Brands recorded a 3% increase, totaling USD 915 million, although the Others segment saw a decline of 42%, contributing just USD 19 million.
Key drivers for Organon included three biosimilars: Ontruzant (trastuzumab) saw a remarkable 76% sales increase, fueled by strong demand in the U.S.; Renflexis (infliximab) grew 28%, with Brazil playing a significant role; and Hadlima (adalimumab) more than doubled its sales in Q4 following its U.S. launch in July 2022. In the Women’s Health segment, fertility products continued to be growth leaders, particularly the Follistim (follitropin beta injection) family, with China emerging as a crucial market. Sales of oral contraceptives Marvelon (ethinylestradiol, desogestrel) and Mercilon (ethinylestradiol, desogestrel) also benefited from the reacquisition of rights in select Southeast Asian and Chinese territories in 2022. Notably, sales in China increased from USD 196 million to USD 203 million in Q4 2023, reflecting a 3.5% growth according to the calculations, although annual sales in China decreased from USD 917 million to USD 864 million, a decline of 5.8%.- Flcube.com
